Keros Therapeutics, INC Form 4 insider transactions

Jean Jacques Bienaime, a Director of Keros Therapeutics, Inc., purchased 1,000 shares of common stock on July 15, 2026 for $10.61 per share.

Keros Therapeutics, Inc. reports that Director Anne Prener was granted restricted stock units and stock options on July 1, 2026.

Keros Therapeutics, Inc. reports that Director Jean Jacques Bienaime purchased 1,000 shares of common stock under a pre-arranged trading plan.

Director Nima Farzan sold 2,625 shares of Keros Therapeutics common stock via a pre-arranged 10b5-1 trading plan.

Keros Therapeutics Director Julius Knowles sold 2,625 shares of common stock for $10.73 per share under a pre-arranged trading plan.

Director Alpna Seth acquired 7,142 restricted stock units and 7,433 stock options in Keros Therapeutics, Inc.

Director Alpna Seth sold 2,625 shares of Keros Therapeutics, Inc. common stock on June 4, 2026, pursuant to a Rule 10b5-1 trading plan.

Director Mary Ann Gray acquired 7,142 restricted stock units and 7,433 stock options in Keros Therapeutics.

Director Julius Knowles received a grant of 7,142 restricted stock units and 7,433 stock options from Keros Therapeutics.

Director Jean-Jacques Bienaime acquired 1,000 shares of Keros Therapeutics, Inc. (KROS) at an average price of $11.70.

Keros Therapeutics CEO Jasbir Seehra acquired 55,000 shares of common stock at $0.30 per share, increasing his beneficial ownership.

Keros Therapeutics, Inc. filed an amended Form 4 to correct the transaction date for Chief Legal Officer Esther Cho's grant of 80,000 employee stock options.

Keros Therapeutics' CEO, Jasbir Seehra, was granted 317,000 employee stock options with an exercise price of $15.52, subject to time-based and performance-based vesting.

Keros Therapeutics' Chief Financial Officer, Keith Regnante, was granted 60,000 employee stock options with an exercise price of $15.52.

Keros Therapeutics' Chief Legal Officer, Esther Cho, was granted 80,000 employee stock options with an exercise price of $15.52 per share.

Keros Therapeutics' Chief Scientific Officer, Lorena Raquel Lerner, was granted 75,000 employee stock options with an exercise price of $15.52.

Keros Therapeutics CEO Jasbir Seehra's performance-based stock options saw 62,500 shares vest, while an equal amount was forfeited due to unmet conditions.

OrbiMed Advisors and related entities disposed of over 214,000 shares of Keros Therapeutics common stock at $17.75 per share in connection with a tender offer.

Keros Therapeutics Director Carl L. Gordon disposed of 214,522 shares of common stock at $17.75 per share in connection with a cash tender offer.

Keros Therapeutics director Julius Knowles disposed of 322,021 shares of common stock at $17.75 per share through a company tender offer.

Pontifax Management and affiliated funds, along with directors Tomer Kariv and Ran Nussbaum, have sold their entire beneficial ownership in Keros Therapeutics, Inc. for approximately $84.9 million, coinciding with the directors' resignations.

ADAR1 Capital Management and related entities reported the planned sale of over 5.3 million shares of Keros Therapeutics common stock for approximately $95.6 million.

Keros Therapeutics CEO Jasbir Seehra received an award of 90,500 restricted stock units, vesting over four years.

ADAR1 Capital Management, a 10% owner and director of Keros Therapeutics, Inc., reported the disposition of 1,700 shares of common stock and the closing of several put option positions on June 20, 2025.

ADAR1 Capital Management and related entities have filed a Form 4 indicating the expiration of put options on Keros Therapeutics, Inc. common stock, with a strike price of $10, resulting in no beneficial ownership of these derivative securities following the transactions.

Keros Therapeutics, Inc. Director and 10% Owner, Tomer Kariv, has filed an amended Form 4 to disclose 155,262 shares of common stock held indirectly, which were inadvertently omitted from prior filings.

Ran Nussbaum, a Director and 10% owner of Keros Therapeutics, Inc., has filed an amended Form 4 to correct the inadvertent omission of 155,262 indirectly held common shares.

Keros Therapeutics, Inc. director Alpna Seth received grants of 5,250 restricted stock units and options to purchase 10,500 shares of common stock, linking her compensation directly to the company's future success.

Keros Therapeutics, Inc. Director Mary Ann Gray was granted 5,250 restricted stock units and 10,500 stock options on June 4, 2025, as part of her compensation.

Keros Therapeutics, Inc. Director Julius Knowles has reported the acquisition of restricted stock units and stock options, aligning his interests with shareholders.